We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00029159
Recruitment Status : Completed
First Posted : January 9, 2002
Last Update Posted : June 5, 2012
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purposes of this study are to learn whether treatment with an androgen type hormone will improve the visual-spatial problems associated with Turner syndrome, and to evaluate the effect growth hormone, with and without androgen, has on growth.

Condition or disease Intervention/treatment Phase
Turner Syndrome Drug: estrogen Drug: androgen Other: placebo Phase 3

Detailed Description:
Turner syndrome is associated with short stature, multiple physical stigmata, absent pubertal development, and increased learning problems. This study is designed to (1) examine the effects of sex steroids (androgen and estrogen) on multiple variables including growth rate, GH binding protein, IGF-I, IGFBP3, and cognitive function in the setting of supplemental growth hormone administration and (2) to investigate any synergistic or additive effects of the androgen and estrogen combination versus each alone, on the above variables.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome
Study Start Date : November 1992
Primary Completion Date : January 2007
Study Completion Date : June 2012


Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1 Drug: estrogen
Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
Drug: androgen
Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
Placebo Comparator: 2 Drug: estrogen
Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
Other: placebo
an inactive substance


Outcome Measures

Primary Outcome Measures :
  1. Cognitive function in girls with Turner Syndrome [ Time Frame: 4 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years to 14 Years   (Child)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria
  • Karyotype diagnosis compatible with Turner syndrome, but no presence of any Y material in the peripheral karyotype unless a gonadectomy has been performed;
  • Chronological age between 10.0 and 14.9 years;
  • Bone age less than or equal to 12 years; and
  • No treatment with estrogen, androgen, growth hormone, or any other growth-promoting agents exceeding 12 months, and no treatment with any of these agents in the previous 3 months.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029159


Locations
United States, Maryland
National Institutes of Health
Bethesda, Maryland, United States, 20892
United States, Pennsylvania
Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 726
Philadelphia, Pennsylvania, United States, 19102
Sponsors and Collaborators
Thomas Jefferson University
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Judith L. Ross, M.D. Thomas Jefferson University
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT00029159     History of Changes
Other Study ID Numbers: R01NS032531 ( U.S. NIH Grant/Contract )
First Posted: January 9, 2002    Key Record Dates
Last Update Posted: June 5, 2012
Last Verified: June 2012

Keywords provided by Thomas Jefferson University:
Turner syndrome
estrogen
androgen
growth hormone

Additional relevant MeSH terms:
Turner Syndrome
Gonadal Dysgenesis
Primary Ovarian Insufficiency
Syndrome
Disease
Pathologic Processes
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn
Gonadal Disorders
Endocrine System Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Hormones
Estrogens, Conjugated (USP)
Methyltestosterone
Estrogens
Androgens
Ascorbic Acid
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs